Optimizing urate-lowering therapy to achieve target serum urate levels may not harm, and may benefit ... absolute risk and an 11% lower relative risk of kidney function decline to an estimated ...

Calcium levels decreased less with each subsequent denosumab dose among individuals with osteoporosis and advanced chronic kidney disease.

Some 20% to 30% of gout patients also have CKD, the researchers said, which is not surprising since they share many risk ...

A technology has been developed that can analyze tumor mutations in lung cancer patients to confirm drug resistance to ...

Without a reliable way to self-regulate blood glucose levels, patients are forced to live with a high-maintenance regimen of ...

This week Novartis NVS upgraded its mid-term sales growth guidance. The European Commission approved Pfizer’s PFE hemophilia ...

When complex multicellular organisms grow and develop, their tissues must undergo remodeling. As new cells begin to ...

and novel agents (e.g. tirapazamine, EGFR inhibitors and other targeted agents) with radiotherapy will be examined. This article is part one of two articles. In the subsequent article, the general ...

In this target trial emulation study, denosumab was found to increase the risk of hypocalcemia requiring emergency treatment ...

Treatment with the potassium binder sodium zirconium cyclosilicate (SZC; Lokelma) stabilized potassium levels among patients ...

After hours: November 22 at 5:30 PM EST Loading Chart for GFR ...

Discover how kidney function decline in ATTR-CM patients predicts higher mortality, highlighting its role as a critical marker in disease management and care optimisation.